Neurotherapeutics

, Volume 7, Issue 3, pp 307–319 | Cite as

Complementary and alternative medicine in autism: An evidence-based approach to negotiating safe and efficacious interventions with families

  • R. Scott Akins
  • Kathy Angkustsiri
  • Robin L. Hansen
Review Article

Summary

This review focuses on helping clinicians identify resources and develop strategies they may use to effectively negotiate safe and effective use of complementary and alternative medicine (CAM) treatments with families of children with autism spectrum disorders (ASD), as well as other neurodevelopmental disorders. Since new types of CAM continue to be introduced into the autism community, emphasis is placed on providing clinicians with tools to help families negotiate the myriad of available treatments and make decisions based on current safety and efficacy data, while remaining mindful of the reasons families may be considering these treatments. We familiarize readers with high-quality, evidence-based resources that providers and families may use to ascertain current information about specific types of CAM, verify the content of biologically-based treatments, identify ongoing CAM research and obtain toolkits designed to help healthcare providers raise the topic of CAM usage and facilitate disclosure and discussion of CAM use with patients and their families.

Key Words

Complementary and alternative medicine autism integrative medicine gluten-free casein-free diet melatonin chelation hyperbaric oxygen treatment evidence-based medicine 

References

  1. 1.
    Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007;37: 628–636.PubMedGoogle Scholar
  2. 2.
    American Academy of Pediatrics; Committee on Children with Disabilities. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability [Erratum in: Pediatrics 2001;108:507]. Pediatrics 2001;107: 598–601.Google Scholar
  3. 3.
    Kemper KJ, Vohra S, Walls R; American Academy of Pediatrics; Task Force on Complementary and Alternative Medicine; Provisional Section on Complementary, Holistic, and Integrative Medicine. The use of complementary and alternative medicine in pediatrics. Pediatrics 2008;122: 1374–1386.PubMedGoogle Scholar
  4. 4.
    Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders: Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009;58(10): 1–20.Google Scholar
  5. 5.
    American Psychiatric Association; Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.Google Scholar
  6. 6.
    Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics 2007;120: 1162–1182.PubMedGoogle Scholar
  7. 7.
    Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil 2007;28: 341–352.PubMedGoogle Scholar
  8. 8.
    Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006;16: 181–186.PubMedGoogle Scholar
  9. 9.
    Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006;36: 901–909.PubMedGoogle Scholar
  10. 10.
    Veenstra-Vanderweele J, Christian SL, Cook EH Jr. Autism as a paradigmatic complex genetic disorder. Annu Rev Genomics Hum Genet 2004;5: 379–405.PubMedGoogle Scholar
  11. 11.
    Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J Dev Neurosci 2005;23: 189–199.PubMedGoogle Scholar
  12. 12.
    Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009: 20: 84–90.PubMedGoogle Scholar
  13. 13.
    Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008;17: 787–801, viii-ix.PubMedGoogle Scholar
  14. 14.
    King BH, Hollander E, Sikich L, et al.; STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66: 583–590.PubMedGoogle Scholar
  15. 15.
    Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007;120: 1183–1215.PubMedGoogle Scholar
  16. 16.
    National standards report. Randolph, MA: National Autism Center, 2009. Available at: http://www.nationalautismcenter.org/.Google Scholar
  17. 17.
    Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008;37: 8–38.PubMedGoogle Scholar
  18. 18.
    Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124: 1533–1540.PubMedGoogle Scholar
  19. 19.
    Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007;61: 538–544.PubMedGoogle Scholar
  20. 20.
    Medical Home Services for Autism Spectrum Disorders. Madison, WI: Waisman Center, University of Wisconsin-Madison, University Center for Excellence in Developmental Disabilities, National Medical Home Autism Initiative, 2008. Available at http://www.waisman.wisc.edu/cedd/guidelines/.Google Scholar
  21. 21.
    Levy SE, Hyman SL. Use of complementary and alternative treatments for children with autistic spectrum disorders is increasing. Pediatr Ann 2003;32: 685–691.PubMedGoogle Scholar
  22. 22.
    Mandell DS, Novak M. The role of culture in families’ treatment decisions for children with autism spectrum disorders. Ment Retard Dev Disabil Res Rev 2005;11: 110–115.PubMedGoogle Scholar
  23. 23.
    Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008:(10):1–23.Google Scholar
  24. 24.
    Mitzdorf U, Beck K, Horton-Hausknecht J, et al. Why do patients seek treatment in hospitals of complementary medicine? J Altern Complement Med 1999;5: 463–473.PubMedGoogle Scholar
  25. 25.
    Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr 2006;27(2 Suppl): S156-S161.PubMedGoogle Scholar
  26. 26.
    Nickel RE, Gerlach EK. The use of complementary and alternative therapies by the families of children with chronic conditions and disabilities. Inf Young Children 2001;14(1): 67–78.Google Scholar
  27. 27.
    Kramer LS. Uncommon voyage: parenting a special needs child in the world of alternative medicine. 1st ed. Boston: Faber & Faber, 1996.Google Scholar
  28. 28.
    Mattheis P. Alternative therapies: From a parent’s perspective. In: Hassold TJ, Patterson D. Down syndrome: a promising future, together. New York: Wiley-Liss, 1999: 93–100.Google Scholar
  29. 29.
    Prussing E, Sobo EJ, Walker E, Kurtin PS. Between ‘desperation’ and disability rights: a narrative analysis of complementary/alternative medicine use by parents for children with Down syndrome. Soc Sci Med 2005;60: 587–598.PubMedGoogle Scholar
  30. 30.
    McCaffrey AM, Pugh GF, O’Connor BB. Understanding patient preference for integrative medical care: results from patient focus groups. J Gen Intern Med 2007;22: 1500–1505.PubMedGoogle Scholar
  31. 31.
    Simpson N, Roman K. Complementary medicine use in children: extent and reasons. A population-based study. Br J Gen Pract 2001;51: 914–916.PubMedGoogle Scholar
  32. 32.
    Spigelblatt L, Laîné-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. Pediatrics 1994;94: 811–814.PubMedGoogle Scholar
  33. 33.
    American Academy of Pediatrics; Division of Health Policy Research; Periodic Survey of Fellows. Periodic survey #49: complementary and alternative medicine (CAM) therapies in pediatric practices, 2001. Elk Grove Village, IL: American Academy of Pediatrics, October 2002. Executive summary available at: http://www.aap.org/research/periodicsurvey/ps49bexs.htm.Google Scholar
  34. 34.
    Pitetti R, Singh S, Hornyak D, Garcia SE, Herr S. Complementary and alternative medicine use in children. Pediatr Emerg Care 2001;17: 165–169.PubMedGoogle Scholar
  35. 35.
    Kaplan SH, Greenfield S, Ware JE Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease [Erratum in: Med Care 1989;27:679]. Med Care 1989;27(3 Suppl): S110-S127.PubMedGoogle Scholar
  36. 36.
    Bayat M. Evidence of resilience in families of children with autism. J InteUect Disabil Res 2007;51: 702–714.Google Scholar
  37. 37.
    Roth R. Medicine’s ethical responsibilities. In: Veatch RM, editor. Cross-cultural perspectives in medical ethics: readings. 1st ed. Sudbury, MA: Jones & Bartlett, 1989;150–155.Google Scholar
  38. 38.
    Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med 1997;127: 61–69.PubMedGoogle Scholar
  39. 39.
    Sugarman J, Burk L. Physicians’ ethical obligations regarding alternative medicine. JAMA 1998;280: 1623–1625.PubMedGoogle Scholar
  40. 40.
    Lynöe N. Ethical and professional aspects of the practice of alternative medicine. Scand J Soc Med 1992;20: 217–225.PubMedGoogle Scholar
  41. 41.
    Sackett D, Rosenberg W, Gray J, Haynes R, Richardson W. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312: 71–2.PubMedGoogle Scholar
  42. 42.
    Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008;17: 803–820, ix.PubMedGoogle Scholar
  43. 43.
    Pham B, Klassen TP, Lawson ML, Moher D. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary [Erratum in: J Clin Epidemiol 2006;59:216]. J Clin Epidemiol 2005;58: 769–776.PubMedGoogle Scholar
  44. 44.
    Klassen TP, Pham B, Lawson ML, Moher D. For randomized controlled trials, the quality of reports of complementary and alternative medicine was as good as reports of conventional medicine [Erratum in: J Clin Epidemiol 2006;59:216]. J Clin Epidemiol 2005;58: 763–768.PubMedGoogle Scholar
  45. 45.
    Lawson ML, Pham B, Klassen TP, Moher D. Systematic reviews involving complementary and alternative medicine interventions had higher quality of reporting than conventional medicine reviews [Erratum in: J Clin Epidemiol 2006;59:216]. J Clin Epidemiol 2005;58: 777–784.PubMedGoogle Scholar
  46. 46.
    Cohen MH, Kemper KJ, Stevens L, Hashimoto D, Gilmour J. Pediatric use of complementary therapies: ethical and policy choices. Pediatrics 2005;116: e568-e575.PubMedGoogle Scholar
  47. 47.
    Gold C, Wigram T, Elefant C. Music therapy for autistic spectrum disorder. Cochrane Database Syst Rev 2006;(2):CD004381.Google Scholar
  48. 48.
    Kim J, Wigram T, Gold C. The effects of improvisational music therapy on joint attention behaviors in autistic children: a randomized controlled study. J Autism Dev Disord 2008;38: 1758–1766.PubMedGoogle Scholar
  49. 49.
    Kim J, Wigram T, Gold C. Emotional, motivational and interpersonal responsiveness of children with autism in improvisational music therapy. Autism 2009;13: 389–409.PubMedGoogle Scholar
  50. 50.
    Jensen PS, Kenny DT. The effects of yoga on the attention and behavior of boys with attention-deficit/disorder (ADHD). J Atten Disord 2004;7: 205–216.PubMedGoogle Scholar
  51. 51.
    Uma K, Nagendra HR, Nagarathna R, Vaidehi S, Seethalakshmi R. The integrated approach of yoga: a therapeutic tool for mentally retarded children: a one-year controlled study. J Ment Defic Res 1989;33(Pt 5): 415–421.PubMedGoogle Scholar
  52. 52.
    Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332: 385–393.PubMedGoogle Scholar
  53. 53.
    El-Sherif Y, Tesoriero J, Hogan MV, Wieraszko A. Melatonin regulates neuronal plasticity in the hippocampus. J Neurosci Res 2003;72: 454–460.PubMedGoogle Scholar
  54. 54.
    Limoges E, Mottron L, Bolduc C, Berthiaume C, Godbout R. Atypical sleep architecture and the autism phenotype. Brain 2005;128: 1049–1061.PubMedGoogle Scholar
  55. 55.
    Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008;13: 90–98.PubMedGoogle Scholar
  56. 56.
    Shamseer L, Vohra S. Complementary, holistic, and integrative medicine: melatonin. Pediatr Rev 2009: 30: 223–228.PubMedGoogle Scholar
  57. 57.
    Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006;32: 585–589.PubMedGoogle Scholar
  58. 58.
    Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5: 145–150.PubMedGoogle Scholar
  59. 59.
    Phillips L, Appleton RE. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol 2004;46: 771–775.PubMedGoogle Scholar
  60. 60.
    Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44: 57–64.PubMedGoogle Scholar
  61. 61.
    Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008;23: 482–485.PubMedGoogle Scholar
  62. 62.
    Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351: 1254.PubMedGoogle Scholar
  63. 63.
    Peled N, Shorer Z, Peled E, Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001;42: 1208–1210.PubMedGoogle Scholar
  64. 64.
    Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993;17: 765–774.PubMedGoogle Scholar
  65. 65.
    Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23-2007: a 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med 2007;357: 392–400.PubMedGoogle Scholar
  66. 66.
    Arnold GL, Hyraan SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord 2003;33: 449–454.PubMedGoogle Scholar
  67. 67.
    Clark JH, Rhoden DK, Turner DS. Symptomatic vitamin A and D deficiencies in an eight-year-old with autism. JPEN J Parenter Enteral Nutr 1993;17: 284–286.PubMedGoogle Scholar
  68. 68.
    Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr 2006;83: 191–201.PubMedGoogle Scholar
  69. 69.
    Evans CD, Lacey JEE. Toxicity of vitamins: complications of a health movement. Br Med J (Clin Res Ed) 1986;292: 509–510.Google Scholar
  70. 70.
    Israngkun PP, Newman HA, Patel ST, Duruibe VA, Abou-Issa H. Potential biochemical markers for infantile autism. Neurochem Pathol 1986;5: 51–70.PubMedGoogle Scholar
  71. 71.
    Reichelt KL, Hole K, Hamberger A, et al. Biologically active peptide-containing fractions in schizophrenia and childhood autism. Adv Biochem Psychopharmacol 1981;28: 627–643.PubMedGoogle Scholar
  72. 72.
    Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002;5: 251–261.PubMedGoogle Scholar
  73. 73.
    Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008;(2):CD003498.Google Scholar
  74. 74.
    Elder J, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord 2006;36: 413–420.PubMedGoogle Scholar
  75. 75.
    McCarthy DM, Coleman M. Response of intestinal mucosa to gluten challenge in autistic subjects. Lancet 1979;2(8148): 877–878.PubMedGoogle Scholar
  76. 76.
    Ashwood P, Anthony A, Pellicer AA, Torrente E, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 2003;23: 504–517.PubMedGoogle Scholar
  77. 77.
    Cass H, Gringras P, March J, et al. Absence of urinary opioid peptides in children with autism. Arch Dis Child 2008;93: 745–750.PubMedGoogle Scholar
  78. 78.
    Dettmer K, Hanna D, Whetstone P, Hansen R, Hammock BD. Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. Anal Bioanal Chem 2007;388: 1643–1651.PubMedGoogle Scholar
  79. 79.
    Hediger ML, England LJ, Molloy CA, Yu KE, Manning-Courtney P, Mills JL. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 2008;38: 848–856.PubMedGoogle Scholar
  80. 80.
    Marcason W. What is the current status of research concerning use of a gluten-free, casein-free diet for children diagnosed with autism? J Am Diet Assoc 2009;109: 572.PubMedGoogle Scholar
  81. 81.
    Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001;56: 462–471.PubMedGoogle Scholar
  82. 82.
    Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A 2007;70: 837–851.PubMedGoogle Scholar
  83. 83.
    Rogan WJ, Dietrich KN, Ware JEE, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001;344: 1421–1426.PubMedGoogle Scholar
  84. 84.
    Gracia RC, Snodgrass WR. Lead toxicity and chelation therapy. Am J Health Syst Pharm 2007;64: 45–53.PubMedGoogle Scholar
  85. 85.
    Thompson WW, Price C, Goodson B, et al.; Vaccine Safety Datalink Team. Early thiraerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007;357: 1281–1292.PubMedGoogle Scholar
  86. 86.
    Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis 2009;48: 456–461.PubMedGoogle Scholar
  87. 87.
    Hertz-Picciotto I, Green PG, Delwiche L, Hansen R, Walker C, Pessah IN. Blood mercury concentrations in CHARGE Study children with and without autism. Environ Health Perspect 2010;118: 161–166.PubMedGoogle Scholar
  88. 88.
    Ng DK, Chan CH, Soo MT, Lee RS. Low-level chronic mercury-exposure in children and adolescents: meta-analysis. Pediatr Int 2007;49: 80–87.PubMedGoogle Scholar
  89. 89.
    Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy: Texas, Pennsylvania, and Oregon, 2003–2005. MMWR Morb Mortal Wkly Rep 2006;55: 204–207.Google Scholar
  90. 90.
    Mitka M. Chelation therapy trials halted. JAMA 2008;300: 2236.PubMedGoogle Scholar
  91. 91.
    Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ. Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 2007;115: 201–209.PubMedGoogle Scholar
  92. 92.
    Tsouderos T, Callahan P. Autism’s risky experiments. Chicago Tribune. Nov. 22, 2009:1.Google Scholar
  93. 93.
    Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005;11: 131–142.PubMedGoogle Scholar
  94. 94.
    Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev 2005;(3): CD003495.Google Scholar
  95. 95.
    Crook WG. The yeast connection: a medical breakthrough. 1st ed. Jackson, TN: Professional Books, 1983.Google Scholar
  96. 96.
    Autism Research Institute. Page title [Internet]. Accessed Eeb. 25, 2010. Available at: http://legacy.autism.com/ARI/editorials/ ed_candida.htm.Google Scholar
  97. 97.
    Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem 1995;41: 1094–1104.PubMedGoogle Scholar
  98. 98.
    Undersea & Hyperbaric Medical Society [Internet]. Accessed 25 Feb., 2010. Available at http://www.uhms.org.Google Scholar
  99. 99.
    Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM 2004;97: 385–395.PubMedGoogle Scholar
  100. 100.
    Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004;(1):CD003057.Google Scholar
  101. 101.
    Bennett MH, Wasiak J, Schnabel A, Kranke P, French C. Hyperbaric oxygen therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2005;(3):CD004954.Google Scholar
  102. 102.
    Bennett M, Newton H. Hyperbaric oxygen therapy and cerebral palsy: where to now? Undersea Hyperb Med 2007;34: 69–74.PubMedGoogle Scholar
  103. 103.
    McDonagh MS, Morgan D, Carson S, Russman BS. Systematic review of hyperbaric oxygen therapy for cerebral palsy: the state of the evidence. Dev Med Child Neurol 2007;49: 942–947.PubMedGoogle Scholar
  104. 104.
    Plafki C, Peters P, Almeling M, Welslau W, Busch R. Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med 2000: 71: 119–124.PubMedGoogle Scholar
  105. 105.
    Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses 2006;67: 216–228.PubMedGoogle Scholar
  106. 106.
    Rossignol DA, Rossignol LW, James SJ, Meinyk S, Mumper E. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr 2007;7: 36.PubMedGoogle Scholar
  107. 107.
    Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr 2009;9: 21.PubMedGoogle Scholar
  108. 108.
    Bennett M, Hart B. UHMS position paper: The treatment of autism spectrum disorder with hyperbaric oxygen therapy [Internet]. Dec. 5, 2009. Available at: http://www.uhms.org/portals/0/ pdf/autism_position_paper.pdf.Google Scholar
  109. 109.
    Collet JP, Vanasse M, Marois P, et al.; HBO-CP Research Group. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. Lancet 2001;357: 582–586.PubMedGoogle Scholar
  110. 110.
    Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2005 Oct 19;(4): CD003497.Google Scholar
  111. 111.
    Tolbert L, Haigler T, Waits M, Dennis T. Brief report: lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. J Autism Dev Disord 1993;23: 193–199.PubMedGoogle Scholar
  112. 112.
    Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wiznitzer M. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997;27: 467–478.PubMedGoogle Scholar
  113. 113.
    Kuriyama S, Kamiyama M, Watanabe M, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Dev Med Child Neurol 2002;44: 284–286.PubMedGoogle Scholar
  114. 114.
    Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. J Child Neurol 1988;3 Suppl: S68-S72.PubMedGoogle Scholar
  115. 115.
    Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of l-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002;17: 833.PubMedGoogle Scholar
  116. 116.
    Gilliam JE. Gilliam Autism Rating Scale: GARS. 1st ed. Austin, TX: Pro-Ed, 1995.Google Scholar
  117. 117.
    Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord 2004;34: 615–623.PubMedGoogle Scholar
  118. 118.
    Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000;30: 475–479.PubMedGoogle Scholar
  119. 119.
    Schneider C, Melmed R, Barstow L, Enriquez F, Ranger-Moore J, Ostrem J. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J Autism Dev Disord 2006;36: 1053–1064.PubMedGoogle Scholar
  120. 120.
    Wakefield AJ. The gut-brain axis in childhood developmental disorders. J Pediatr Gastroenterol Nutr 2002;34 Suppl 1: S14-S17.PubMedGoogle Scholar
  121. 121.
    Feasby T, Banwell B, Benstead T, et al.; IVIG Hematology and Neurology Expert Panels. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21(2 Suppl l): S57-S107.PubMedGoogle Scholar
  122. 122.
    Niederhofer H, Staffen W, Mair A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology 2003;28: 1014–1015.PubMedGoogle Scholar
  123. 123.
    Handen BL, Melmed RD, Hansen RL, et al. A Double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord 2009;39: 796–805.PubMedGoogle Scholar
  124. 124.
    Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007;61: 551–553.PubMedGoogle Scholar
  125. 125.
    Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord 2009;39: 1145–1154.PubMedGoogle Scholar
  126. 126.
    Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006;9: 485–499.PubMedGoogle Scholar
  127. 127.
    James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80: 1611–1617.PubMedGoogle Scholar
  128. 128.
    James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141B: 947–956.PubMedGoogle Scholar
  129. 129.
    James SJ, Meinyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89: 425–430.PubMedGoogle Scholar
  130. 130.
    Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord 1999;29: 191–194.PubMedGoogle Scholar
  131. 131.
    Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol 2001;16: 169–173.PubMedGoogle Scholar
  132. 132.
    Khorshid KA, Sweat RW, Zemba DA Jr, Zemba BN. Clinical efficacy of upper cervical versus full spine chiropractic care on children with autism: a randomized clinical trial. J Vertebral Subluxation Res 2006:1–7.Google Scholar
  133. 133.
    Vohra S, Johnston B, Cramer K, Humphreys K. Adverse events associated with pediatric spinal manipulation: a systematic review. Pediatrics 2007;119: e275-e283.PubMedGoogle Scholar
  134. 134.
    Greenman PE. Principles of manipulation of the cervical spine. J Manual Med 1991;6: 106–113.Google Scholar
  135. 135.
    Green C, Martin C, Bassett K, Kazanjian A. A systematic review of craniosacral therapy: biological plausibility, assessment reliability and clinical effectiveness. Complement Ther Med 1999;7: 201–207.PubMedGoogle Scholar
  136. 136.
    Silva LM, Cignolini A, Wanen R, Budden S, Skowron-Gooch A. Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med 2007;35: 393–406.PubMedGoogle Scholar
  137. 137.
    Escalona A, Field T, Singer-Strunck R, Cullen C, Hartshorn K. Brief report: Improvements in the behavior of children with autism following massage therapy. J Autism Dev Disord 2001;31: 513–516.PubMedGoogle Scholar
  138. 138.
    Furlan A, van Tulder M, Cherkin D, et al. Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the Cochrane collaboration. Spine (Phila Pa 1976) 2005;30: 944–963.Google Scholar
  139. 139.
    Mamtani R, Cimino A. A primer of complementary and alternative medicine and its relevance in the treatment of mental health problems. Psychiatr Q 2002;73: 367–381.PubMedGoogle Scholar
  140. 140.
    Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 2005;11: 164–170.PubMedGoogle Scholar
  141. 141.
    Liptak GS. Complementary and alternative therapies for cerebral palsy. Ment Retard Dev Disabil Res Rev 2005;11: 156–163.PubMedGoogle Scholar
  142. 142.
    Carbone PS, Behl DD, Azor V, Murphy NA. The medical home for children with autism spectrum disorders: parent and pediatrician perspectives. J Autism Dev Disord 2010;40: 317–324.PubMedGoogle Scholar
  143. 143.
    Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord 2009;39: 996–1005.PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • R. Scott Akins
    • 1
  • Kathy Angkustsiri
    • 1
  • Robin L. Hansen
    • 1
  1. 1.The M.I.N.D. Institute, PediatricsUniversity of California, DavisSacramento

Personalised recommendations